has unique properties in its ability of binding fat from the food in the stomach and in the intestines. This leads to a correction and normalization of the LDL cholesterol and triglyceride levels in the blood. The HDL-cholesterol level in the blood increases. The fat sucked out of the food and remains in the digestional canal. Thus, the blood takes up less fat which leads to less fat deposits in the body. The body absorbs fewer calories from the fat and the cholesterol and triglyceride levels in the blood are reduced, all in one natural process.
L112 BIOPOLYMER reference
Rossner S, Abelin J:
MATS Medical AB, Stockholm, Sweden, 1995. Abstract: L112 Biopolymer (L112 Fat Blocker) is an investigational drug extracted from shellfish.
L112 Biopolymer has unique properities in its ability of binding fat from the food in the stomach and in the intestines. This leads to a correction and normalization of the LDL cholesterol and triglyceride levels in the blood. The HDL-cholesterol level in the blood increases. The fat sucked out of the food and remains in the digestional canal. Thus the blood takes up less fat which leads to less fat deposits in the body. The body absorbs fewer calories from the fat and the cholesterol and triglyceride levels in the blood are reduced, all in one natural process.
L112 Fat Blocker is made of a special fibre-like substance derived from the shells of shrimps, crabs and ohter shellfishes. After chemical extraction the substances has got electrostatic properties and has unique fat binding properties. It has been tested by a Norwegian research laboratory. When given orally together with the food it immediately disperse into tiny particles.
These have great affinity to fat and starts binding themselves to fat particles in the stomach and upper intestines. With increasing pH in the lower intestines the binding occurs probably through precipitation and the body cannot any longer absorb the fat through the intestinal wall or dispense the into the blood stream.
The substances has been tested in clinical trials and shows a remarkable effect in reducing total cholesterol while allowing the HDL-cholesterol to increase. In one randomized double-blind study with placebo-control the weight reduction was 2.5 times better than diet alone. A preliminary review on L112 Biopolymer has been published elsewhere. When fat contents in the bowel increases, it makes the feces soft and smooth. This may be particularly positive for those who suffer from obstipation. In this unicentre trial the fat content in feces and laboratory parameters, during treatment with L112 twice daily, will be investigated.
How come our L112 BIOPOLYMER from?
OPTIMIZING CHITOSAN CHARACTERISTICS FOR EFFECTIVE USE IN HUMAN WEIGHT-LOSS REGIMENS STUDY
BULLET: ANTI-OBESE AND HYPOLIPIDEMIC EFFECTS OF CHITOSANS IN RATS
What we have learned that flake squidpen-derived chitosans functioned much better than powdered crab and shrimp chitosan in binding fats; corn oil >> beef oil > olive oil > coconut oil. High-molecular-weight (HMW) squid pen chitosan had the highest fat-binding activity; however, the binding was not proportional to degree of deacetylation (DD). The chitosans preferred binding corn oil to olive oil, coconut oil and beef tallow. It is believed that the squidpen chitosans bound all fats better than crab and shrimp chitosans. Hydrophobic force (e.g. adsorption or van der Waals force) rather than electrical attraction is a fundamental factor in undigested (intact) lipid-binding performance of the chitosans. Hydrochloric acid pH 2.0 solution transformed colloidal chitosans into viscous chitosans, while the chitosans were precipitated in water and bicarbonate pH 8.5 solution. Swelling of the chitosans was unchanged in water and bicarbonate environment as in small intestine. Saying that, chitosans with small swelling index (SI) number will not enlarge intestinal luminal tract and make subjects uncomfortable. Formed fat-chitosan complex would be retained in the lumen shortly and excreted in feces eventually. It was found that CTS28 (MW >500 kD, DD >90%) and CTS31 (MW 125-500 kD, DD >90%) chitosans were very large and most effective in binding corn oil and beef tallow. Unfortunately, CTS10 chitosan showed the lowest fat-binding activity. Although they were administered per oral (po) and hydrolyzed partially in the stomach, residual chitosans matrices would retain the fat-binding property in small intestine. Nonetheless, we have not known what affinity of the chitosans for binding digested as well as pre-cooked fats is when compared to the intact (undigested) fats in our current study. Therefore, the chitosans are tested for their binding with pre-cooked fats in vitro. The selected chitosans are also examined for their weight-losing and hypolipidemic effects in prefatten as well as fattening rats. Change of plasma lipid profiles and body weight, liver function and kidney function are monitored in the treated rats.
OBJECTIVES OF THE STUDY
To investigate binding activity of selected chitosans with pre-cooked oils in vitro
To examine weight-losing activity of the chitosans in obese rats
To study effect of the chitosans on plasma lipid profiles in the treated rats
To monitor effect of the chitosans on liver and kidney functions